We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
rajeev vijayakumar
Jun 24, 2016
Thank you for the case. In our practice in India, we prefer Pazopanib 400 mg od to start of initially and rise it to 800 mg if patient tolerates it. Sunitinib at 25 mg od two week on and 1 week off can also be given. We need to monitor LFT and TSH regularly
navdeep singh
Jul 26, 2016
Sorafenib is better tolerated. Start with 200 mg bd .. Then escalate...
Annalisa Bramati
Jul 27, 2016
I agree with both pazopanib starting 400 mg die or sunitinib 25 mg die 2 week on/ 1 week off, following the patient with our multidisciplinary team of cardiologist.
May 07, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Andrew
Fintel
DO
rajeev vijayakumar
Jun 24, 2016
navdeep singh
Jul 26, 2016
Annalisa Bramati
Jul 27, 2016
May 07, 2024
Pending Moderator approval.